Article
Public, Environmental & Occupational Health
Victor Kande Betu Ku Mesu, Wilfried Mutombo Kalonji, Clelia Bardonneau, Olaf Valverde Mordt, Digas Ngolo Tete, Severine Blesson, Francois Simon, Sophie Delhomme, Sonja Bernhard, Helene Mahenzi Mbembo, Christian Mpia Moke, Steven Lumeya Vuvu, Junior Mudji E'kitiak, Felix Akwaso Masa, Melchias Mukendi Ilunga, Dieudonne Mpoyi Muamba Nzambi, Tim Mayala Malu, Serge Kapongo Tshilumbwa, Franck Botalema Bolengi, Mathieu Nkieri Matsho, Crispin Lumbala, Bruno Scherrer, Nathalie Strub-Wourgaft, Antoine Tarral
Summary: The study aimed to assess the safety and efficacy of fexinidazole in early-stage human African trypanosomiasis, showing that fexinidazole is a valuable first-line treatment option in the early stages of g-HAT, with high treatment success rates and no new safety issues observed.
LANCET GLOBAL HEALTH
(2021)
Review
Medicine, General & Internal
Vittoria Lutje, Katrin Probyn, Jorge Seixas, Hanna Bergman, Gemma Villanueva
Summary: The study evaluated the effectiveness and safety of current drugs for treating second-stage Trypanosoma brucei gambiense trypanosomiasis. Oral treatment with fexinidazole is easier to administer but may lead to higher mortality and relapse compared to conventional treatment.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Public, Environmental & Occupational Health
Victor Kande Betu Kumesu, Wilfried Mutombo Kalonji, Clelia Bardonneau, Olaf Valverde Mordt, Digas Ngolo Tete, Severine Blesson, Francois Simon, Sophie Delhomme, Sonja Bernhard, Pathou Nganzobo Ngima, Helene Mahenzi Mbembo, Jean-Pierre Fina Lubaki, Steven Lumeya Vuvu, Willy Kuziena Mindele, Medard Ilunga Wa Kyhi, Guylain Mandula Mokenge, Lewis Kaninda Badibabi, Augustin Kasongo Bonama, Papy Kavunga Lukula, Crispin Lumbala, Bruno Scherrer, Nathalie Strub-Wourgaft, Antoine Tarral
Summary: The multicentre clinical trial of oral fexinidazole in pediatric patients with gambiense human African trypanosomiasis demonstrated that the drug is a safe and effective first-line treatment option across all disease stages.
LANCET GLOBAL HEALTH
(2022)
Article
Public, Environmental & Occupational Health
Olaf Valverde Mordt, Antoine Tarral, Nathalie Strub-Wourgaft
Summary: This article describes the strategy used to simplify the introduction of a new oral treatment for human African trypanosomiasis. The authors discuss various aspects of the drug's development, including determining dosage range, testing food effects, optimizing absorption, establishing partnerships, and preparing for regulatory approval and distribution. The article highlights the importance of early preparation and collaboration in successfully bringing the new treatment to affected regions.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
(2022)
Article
Immunology
Manon Geerts, Nick Van Reet, Sander Leyten, Raf Berghmans, Kat S. Rock, Theresa H. T. Coetzer, Lauren E-A Eyssen, Philippe Buscher
Summary: The newly developed T. b. gambiense inhibition ELISA (g-iELISA) based on the principle of antibody binding showed high specificity and sensitivity, making it suitable for regional laboratories in gHAT endemic countries for monitoring and surveillance.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Mariame Camara, Alseny M'mah Soumah, Hamidou Ilboudo, Christelle Travaille, Caroline Clucas, Anneli Cooper, Nono-Raymond Kuispond Swar, Oumou Camara, Ibrahim Sadissou, Estefania Calvo Alvarez, Aline Crouzols, Jean-Mathieu Bart, Vincent Jamonneau, Mamadou Camara, Annette MacLeod, Bruno Bucheton, Brice Rotureau
Summary: In the study of gambiense human African trypanosomiasis, it was found that live parasites may remain undetected in the blood of some seropositive individuals but are present in their skin. The skin may serve as a potential reservoir for African trypanosomes.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Microbiology
Keneth Iceland Kasozi, Ewan Thomas MacLeod, Susan Christina Welburn
Summary: The resistance of Human African trypanosomiasis (HAT) is a challenge to its eradication. Resistance is associated with changes in pathogen receptors and the loss of certain genes. Clinical studies have shown high failure rates for certain therapies, indicating the presence of resistance.
Article
Biochemistry & Molecular Biology
Tatiana Dias-Guerreiro, Joana Palma-Marques, Patricia Mourata-Goncalves, Graca Alexandre-Pires, Ana Valerio-Bolas, Aurea Gabriel, Telmo Nunes, Wilson Antunes, Isabel Pereira da Fonseca, Marcelo Sousa-Silva, Gabriela Santos-Gomes
Summary: The study showed that TbEVs can establish direct communication with cells of innate and adaptive immunity, influencing the differentiation and expansion of macrophages and T lymphocytes.
Article
Pharmacology & Pharmacy
Antoine Tarral, Lionel Hovsepian, Thierry Duvauchelle, Yves Donazzolo, Mathilde Latreille, Mathieu Felices, Virginie Gualano, Sophie Delhomme, Olaf Valverde Mordt, Severine Blesson, Pascal Voiriot, Nathalie Strub-Wourgaft
Summary: This study determined the best dose regimen for Acoziborole, a novel boron-containing drug for the treatment of HAT. The drug was well tolerated at all tested doses and had a long duration of action. The findings suggest that Acoziborole could potentially be used as a single-dose oral cure for both stages of HAT.
CLINICAL PHARMACOKINETICS
(2023)
Article
Public, Environmental & Occupational Health
Gerardo Priotto, Jose R. Franco, Veerle Lejon, Philippe Buscher, Enock Matovu, Joseph Ndung'u, Sylvain Bieler, Dieudonne Mumba, Nick Van Reet, Paul Verle, Vincent Jamonneau, Pere P. Simarro, Augustin Kadima Ebeja, Dieudonne Sankara, Daniel Argaw Dagne
Summary: Human African trypanosomiasis is a parasitic infection transmitted by the tsetse fly in sub-Saharan Africa. Efforts to eliminate transmission of the disease by 2030 have led to the development of a target product profile for a method to verify the absence of transmission. This method needs to be performed in national or sub-national reference laboratories and have characteristics such as simple specimen collection, no cold-chain requirement, high sensitivity and specificity, high-throughput automated testing, low cost per specimen, and applicability to animals.
BULLETIN OF THE WORLD HEALTH ORGANIZATION
(2023)
Article
Infectious Diseases
Oumou Camara, Mamadou Camara, Laura Cristina Falzon, Hamidou Ilboudo, Jacques Kabore, Charlie Franck Alfred Compaore, Eric Maurice Fevre, Philippe Buscher, Bruno Bucheton, Veerle Lejon
Summary: This study assessed the diagnostic performance of various clinical presentations, rapid diagnostic tests, and reference laboratory tests on dried blood spots for the diagnosis of human African trypanosomiasis (HAT) in Guinea. The results showed that the presence of swollen lymph nodes, important weight loss, severe itching, or motor disorders are simple but accurate clinical criteria for HAT referral. The diagnostic performances of HAT Sero-KSet and SD Bioline HAT are sufficient for referring positives to microscopy.
INFECTIOUS DISEASES OF POVERTY
(2023)
Article
Microbiology
Larson Boundenga, Illich Manfred Mombo, Mouinga-Ondeme Augustin, Ngoubangoye Barthelemy, Patrice Makouloutou Nzassi, Nancy D. Moukodoum, Virginie Rougeron, Franck Prugnolle
Summary: Human African Trypanosomiasis is an infectious disease caused by protozoan parasites. Domestic animals may serve as reservoirs for trypanosomes, including the species responsible for the disease, T. brucei gambiense.
Article
Infectious Diseases
Victor Kande Betu Kumeso, Wilfried Mutombo Kalonji, Sandra Rembry, Olaf Valverde Mordt, Digas Ngolo Tete, Adeline Pretre, Sophie Delhomme, Medard Ilunga Wa Kyhi, Mamadou Camara, Julie Catusse, Stefan Schneitter, Morgane Nusbaumer, Erick Mwamba Miaka, Helene Mahenzi Mbembo, Joseph Makaya Mayawula, Mariame Layba Camara, Felix Akwaso Massa, Lewis Kaninda Badibabi, Augustin Kasongo Bonama, Papy Kavunga Lukula, Sylvain Mutanda Kalonji, Phyll Mariero Philemon, Ricardo Mokilifi Nganyonyi, Hugues Embana Mankiara, Andre Asuka Akongo Nguba, Vincent Kobo Muanza, Ernest Mulenge Nasandhel, Aimee Fifi Nzeza Bambuwu, Bruno Scherrer, Nathalie Strub-Wourgaft, Antoine Tarral
Summary: This study aimed to assess the safety and efficacy of acoziborole in patients with late-stage Gambiense HAT, and the results showed that acoziborole is highly effective and safe in treating this disease. This study is of great importance in achieving the WHO goal of interrupting HAT transmission by 2030.
LANCET INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Ipos Ngay Lukusa, Nick Van Reet, Dieudonne Mumba Ngoyi, Erick Mwamba Miaka, Justin Masumu, Pati Patient Pyana, Wilfried Mutombo, Digas Ngolo, Vincent Kobo, Felix Akwaso, Medard Ilunga, Lewis Kaninda, Sylvain Mutanda, Dieudonne Mpoyi Muamba, Olaf Valverde Mordt, Antoine Tarral, Sandra Rembry, Philippe Buscher, Veerle Lejone
Summary: The detection of spliced leader (SL)-RNA shows high specificity and sensitivity in the assessment of treatment outcomes for gambiense human African trypanosomiasis (HAT), allowing the detection of relapses without the need for lumbar puncture.
Article
Medicine, General & Internal
Raquel Inocencio da Luz, Sara Tablado Alonso, Philippe Buescher, Paul Verle, Anja De Weggheleire, Dieudonne Mumba Ngoyi, Pati Patient Pyana, Epco Hasker
Summary: The incidence of gambiense human African trypanosomiasis (gHAT) has reached an all-time low, and new diagnostic tools and treatments offer the opportunity to interrupt transmission by 2030. However, further research is needed to adapt these advances to new control strategies.
